linjc16/ctgov huggingface dataset:
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.

Conditions
-----------------
Glaucoma, Open-Angle, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: 0.03% Bimatoprost


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of open-angle glaucoma or ocular hypertension No use of Lumigan® in the past 3 months Exclusion Criteria: Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 0.03% Bimatoprost<br>0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks. | Drug: 0.03% Bimatoprost<br>* 0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.<br>* Other names: LUMIGAN®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in Intraocular Pressure (IOP) in the Study Eye | IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening). | Baseline, Week 5 |
Real-world Clinical Study and Medical Machine Intelligence Study for Traditional Chinese Internal Medicine

Study Overview
=================
Brief Summary
-----------------
This real-world study aimed at 1. exploring the relationships of traditional Chinese medicine (TCM) syndrome and internal diseases, 2. investigating the relationships of TCM treatment and internal diseases, and 3. creating medical machine intelligence to help internal physician in clinical practice. Big data methods and artificial intelligence algorithms are used to assess the associations based on electronic case files of patients.

Official Title
-----------------
Real-world Clinical Study and Medical Machine Intelligence Study for Traditional Chinese Internal Medicine by Using Medical Big Data and Artificial Intelligence Methods

Conditions
-----------------
Internal Disorders

Intervention / Treatment
-----------------
* Other: regular medical treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patient records of internal medicine in hospital Exclusion Criteria: subjects with major missing data

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group<br> | Other: regular medical treatment<br>* regular medical treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| internal diseases | all of internal diseases | 10 years |
Comparing Warm Versus Cool Temperature Water During Colonoscopy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study will be to determine if the temperature of water used during insertion of colonoscopy makes a difference in patient discomfort and sedation requirements. The hypothesis of this study is patients receiving screening colonoscopy utilizing the water insertion method with room temperature (cool) water will have similar pain scores and medication requirements compared to water insertion method using body temperature (warm) water.

Official Title
-----------------
Comparing Warm Versus Cool Temperature Water During Colonoscopy

Conditions
-----------------
Colonoscopy

Intervention / Treatment
-----------------
* Procedure: Warm vs Cool water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults aged 18 to 85 years undergoing elective outpatient screening colonoscopy for colon cancer screening Exclusion Criteria: Patients undergoing colonoscopy for any other indication besides colon cancer screening Patients with prior colonic resections Patients with chronic narcotic or benzodiazepine use Poor bowel preparation (i.e. Boston bowel preparation score < 8) Patients with obstructing colonic lesions detected on colonoscopy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Warm water<br>Body temperature (95-100 degrees F) water | Procedure: Warm vs Cool water<br>* Body vs Room temperature water used during insertion of colonoscopy<br>|
| Experimental: Cool water<br>Room temperature (68-73 degrees F) water | Procedure: Warm vs Cool water<br>* Body vs Room temperature water used during insertion of colonoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose of sedation medication used (fentanyl and midazolam) |  | Duration of the colonoscopy; Up to 3 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient pain/discomfort score |  | During the day of the procedure; Up to 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colonoscopy, colon cancer screening, patient discomfort scores, sedation medication requirements, water insertion method
Gastric Residuals in Preterm Infants

Study Overview
=================
Brief Summary
-----------------
Checking of gastric residuals prior to the continuation/increase of enteral feeding prolongs the time to establish full gastric feeding in the early postnatal period.

Official Title
-----------------
Gastric Residuals in Preterm Infants (GRIP)

Conditions
-----------------
Early Enteral Feeding Advancement, Nutrition, Preterm Infants

Intervention / Treatment
-----------------
* Procedure: No check of gastric residuals for early enteral feeding advancement
* Procedure: Routine check of gastric residuals for early enteral feeding advancement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants with a birth weight ≥ 1500g and < 2000g Age ≤48 hours of life Informed, written parental consent Exclusion Criteria: Antenatally recognized gastrointestinal malformation Major congenital anomaly Chromosomal anomaly NEC stage II Severe acidosis, asphyxia (pH <7.0) Severe growth restriction below 3rd percentile

Ages Eligible for Study
-----------------
Maximum Age: 48 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: No routine check for gastric residuals<br> | Procedure: No check of gastric residuals for early enteral feeding advancement<br>* Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.<br>|
| Active Comparator: Routine check for gastric residuals<br> | Procedure: Routine check of gastric residuals for early enteral feeding advancement<br>* Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to reach full enteral feeding | Full enteral feeding is defned as an milk intake of equal or more than 120 ml/kg/d. | from inclusion (during first 48h of life) until 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| growth, tolerance, morbidity | Time to regain birth weight and maintain weight gain. Incidence of sepsis from birth until 48 hours after parenteral nutrition was administered. Use of antibiotics. Incidence of feeding intolerance and necrotizing enterocolitis. | from inclusion (during first 48h of life) until one month |
Evaluation of Surgical and Obstetric Outcomes in Pregnant Women Undergoing Operative Laparoscopy

Study Overview
=================
Brief Summary
-----------------
Laparoscopy, when applicable, is the current gold standard management for abdominal and pelvic surgery. Although accumulating evidence suggests that laparoscopy is associated with reduced intraoperative and postoperative morbidity, reduced hospital stay, better recovery and cosmesis compared with open surgery (laparotomy), the use of this technique in pregnant women is still debated. Considering this point, we aimed to collect retrospectively cases of laparoscopic surgery during pregnancy, regardless of the indication and gestational age, in order to analyze both surgical and obstetric outcomes during and after the procedure.

Official Title
-----------------
Evaluation of Surgical and Obstetric Outcomes in Pregnant Women Undergoing Operative Laparoscopy

Conditions
-----------------
Pregnancy Related, Laparoscopy

Intervention / Treatment
-----------------
* Procedure: Laparoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women (regardless of gestational age) At least one indication for laparoscopic surgery Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pregnant women<br>Pregnant women, regardless of the gestational age. | Procedure: Laparoscopy<br>* Diagnostic/operative laparoscopic procedure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraoperative complication | Any complication during laparoscopy | From the beginning to the end of laparoscopy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pregnancy, Laparoscopy
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)

Study Overview
=================
Brief Summary
-----------------
Primary biliary cirrhosis (PBC) is a disease of the liver, which predominantly affects women. It causes slowly progressive liver disease, which eventually causes liver failure, requiring a liver transplant. Several different studies of large patient cohorts indicate that the cause of this disease is likely due to a combination of factors including genetic and environmental. PBC is associated with several other autoimmune diseases - recently a gene has been identified to be abnormal in individuals with another autoimmune liver disease, namely rheumatoid arthritis. This gene usually tells the body when to switch off an immune response. This study plans to identify whether individuals diagnosed with PBC have a similar abnormality in this gene called protein Tyrosine Phosphatase.

Detailed Description
-----------------
Very recently, a single nucleotide polymorphism (SNP) in the PTPN22 gene encoding the Lyp (lymphoid-specific phosphatase) PTP has been shown to be associated with susceptibility to rheumatoid arthritis (RA) and Type 1 diabetes (T1D)4,5. These data are consistent with the known role for Lyp in suppressing T cell activation and with data showing T cell activation (and potentially autoreactivity) to be increased by the RA and T1D-associated PTPN22 variant. The PTPN22 risk allele has also been recently implicated in Grave's disease and as such appears to represent a susceptibility allele for many autoimmune diseases. As a number of these conditions (RA, T1D etc.) frequently occur within members of PBC families, this PTPN22 variant is very likely to also be involved in PBC, a possibility we will directly investigate in this pilot study. The aim of this study is to analyze the frequency of a specific PTPN22 polymorphism in patients with PBC.

Official Title
-----------------
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)

Conditions
-----------------
Liver Cirrhosis, Biliary, Biliary Cirrhosis, Primary

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients attending Liver Clinic at Toronto Western Hospital, Toronto, ON, Canada AMA positive and liver biopsy proven PBC. Exclusion Criteria: - AMA negative PBC

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genes, Biliary Cirrhosis, Primary, autoimmune disease
Computerized Vestibular Rehabilitation

Study Overview
=================
Brief Summary
-----------------
Disorders of vestibular function and balance are an important component of many conditions that commonly affect veterans, such as inner ear diseases, diabetes, and traumatic brain injury. Veterans with vestibular impairment have reduced quality of life, limitations on work and physical activities, and an increased risk of falls. The goal of this research is to develop a more engaging and effective interactive tool for vestibular rehabilitation to improve the lives of affected veterans. The first steps in this process will be to test the ability of the application to facilitate vestibular learning and to test its feasibility in vestibular patients. The hypothesis is that computer-game-based adaptation will induce robust VOR motor learning and will provide an engaging platform for vestibular rehabilitation. Ultimately, our application has the potential to provide more flexible vestibular exercises that will allow therapy to be customized for each patient. It will also have the ability to track a patient's progress over time and to advance exercises as function improves.

Official Title
-----------------
Computerized Game-based Vestibular Rehabilitation: Assessment of Feasibility and Motor Learning

Conditions
-----------------
Vestibular Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: GROUP 1: Healthy volunteers: Static visual acuity of at least 20/30 at testing distance GROUP 2: Vestibular patients: Unilateral or bilateral vestibular hypofunction, No central vestibular disorder, Static Visual Acuity of at least 20/30 at testing distance Exclusion Criteria: GROUP 1: Peripheral or central vestibular disorder GROUP 2: Central vestibular disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal Volunteers<br>Testing motor learning | |
| Vestibular hypofunction<br>Testing feasibility of rehabilitation game | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vestibulo-ocular reflex gain | The vestibulo-ocular reflex gain is the relationship between a rotation of the head and the evoked eye movement. | Immediate | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neurologic rehabilitation, computer games
A Pathology Reference Laboratory for the Study of Infectious Diseases and Malignant Lymphoma

Study Overview
=================
Brief Summary
-----------------
To establish a pathology reference laboratory for the consultation on the diagnosis of infectious diseases and lymphoma. To study the specific pathogens on 100 cases of unexplained death due to infectious diseases in the files of Taiwan CDC and the Forensic Institutes of Department of Law and Justice. To study the distribution of children lymphoid lesions in Vietnam and Taiwan and their virus association. To establish a tissue bank for infectious diseases and lymphoma.

Official Title
-----------------
A Pathology Reference Laboratory for the Study of Infectious Diseases and Malignant Lymphoma

Conditions
-----------------
Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of infectious diseases and lymphoma. Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia

Study Overview
=================
Brief Summary
-----------------
This multicenter, prospective, non-interventional study will evaluate the prevalence and characteristics of patients with persistent symptoms of schizophrenia and the course of their illness over 24 months.

Official Title
-----------------
A Non-Interventional Prospective Cohort Study of Patients With Persistent Symptoms of Schizophrenia to Describe The Course and Burden of Illness

Conditions
-----------------
Schizophrenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients: Adult patients, >/= 18 years of age Diagnosis of schizophrenia according to Diagnostic and Statistical Manual for Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) or International Classification of Diseases, 10th revision (ICD-10) Caregivers: Age >/= 18 years Family member or friend of the patient, who spends at least 4 hours a week with the patient Exclusion Criteria: Acute psychotic exacerbation in the 3 months prior to the baseline observation (e.g. hospitalization or increased psychiatric care in order to prevent hospitalization) Enrolled in an interventional study at the baseline observation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Course of illness: Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) scores |  | from baseline to Month 24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency/characteristics (PANSS) of patients with diagnosis of schizophrenia of >/= 12 months duration before baseline |  | at screening (approximately 18 months) | 
| Duration/severity of symptoms of schizophrenia according to Personal Social Performance Scale (PSP) / Health Related Quality of Life (HRQoL) questionnaire |  | 24 months | 
| Medical resource utilization/costs |  | 24 months |
Once-daily Fixed Combination of Three Antihypertensive Drugs

Study Overview
=================
Brief Summary
-----------------
Randomized comparison of once-daily fixed combiNation versus free-drug combination of three antihypertensive agents in arterial hypertension

Detailed Description
-----------------
The aim of this randomized study is to compare a once-daily fixed combination pill with a free-drug combination of three antihypertensive agents in arterial hypertension

Official Title
-----------------
Randomized Comparison of Once-daily Fixed combiNation vErsus freE-drug cOmbination of Three aNtihypertensive Agents in arteriaL hYpertension (the ONE&ONLY Trial)

Conditions
-----------------
Arterial Hypertension

Intervention / Treatment
-----------------
* Drug: perindopril, indapamide , amlodipine
* Drug: Tripliam (perindopril, indapamide, amlodipine)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with arterial hypertension resistant to monotherapy Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Free combination<br>Perindopril 10 mg/daily, indapamide 2,5 mg/daily, and amlodipine 10 mg/daily will be given according to a free combination strategy | Drug: perindopril, indapamide , amlodipine<br>* Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg<br>* Other names: Procaptan, Indapamide, Norvasc;|
| Active Comparator: Tripliam<br>fixed combination of perindopril 10 mg/daily, indapamide 2,5 mg/daily, amlodipine 10 mg/daily | Drug: Tripliam (perindopril, indapamide, amlodipine)<br>* Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg<br>* Other names: Fixed combination of Procaptan, Indapamide, Norvasc;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who reach target blood pressure | How many patients have blood pressure within normal limits | From baseline to the end of the 3-month study period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
arterial hypertension, antihypertensive drugs